KONEXBiotech & Pharma446440

Epi Biotech

₩14,560▼ 14.30%2026-10-02 close

Market Cap

₩33.6B

Turnover

₩6,847,800

Volume

450 shares

Shares out.

2.3M

PER

—

PBR

—

EPS

—

Dividend Yield

—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Alopecia-Focused Biotech Pursuing Clinical Progress and Revenue in Tandem

Epi Biotech is advancing a self-sustaining biotech model by running its dermal papilla cell therapy (EPI-001) through clinical trials while building revenue from high-margin CRO services and functional alopecia cosmetics.

1
EPI-001 Phase 1/2a Ongoing — Autologous dermal papilla cell therapy received domestic IND approval in December 2023; selected for government Pan-Ministry Regenerative Medicine Program in April 2024
2
CRO Operating Margin Exceeds 50% — Preclinical alopecia CRO services drive high-margin profitability; first overseas contract with a U.S. biotech secured at end of 2024
3
Diversified Pipeline — Multiple modalities including EPI-001 (autologous), EPI-008 (allogeneic), EPI-005 (CXCL12 antibody), and EPI-002 (RIPK1 inhibitor) reduce reliance on any single asset
4
China Joint Venture Initiated — 2025 MOU with Beijing Northland Biotech to establish a JV and pursue clinical trials and commercialization in the fast-growing Chinese alopecia market
5
KOSDAQ Technology-Based Listing Targeted — CEO publicly announced pursuit of a KOSDAQ special listing at Bio Japan 2025, raising prospects for a significant re-rating in liquidity and valuation

Business structure

Epi Biotech was established in December 2015 under the name 'Stemmore,' rebranded in 2021, and listed on the KONEX market in July 2023. Its core business is alopecia drug R&D, covering multiple modalities—cell therapy, antibody therapeutics, gene therapy, and topical small-molecule drugs—simultaneously.

The company operates its own GMP facility, enabling both in-house production of pipeline candidates and contract manufacturing services.

Revenue is structured around three pillars: (1) preclinical alopecia CRO services with reported operating margins above 50%, (2) hair loss research cell line sales, and (3) functional alopecia cosmetics.

The company operates the AI platform 'Hair.I,' integrating a hair loss gene database (EPIGene) and efficacy analytics (EPICacy) to support data-driven drug discovery alongside its CRO business.

Competitive peers include Japan's Shiseido (using DSC-like follicular cells) and a range of global biotech and cosmetics companies; Epi Biotech differentiates on using dermal papilla cells—regarded as master regulators of the hair cycle—as its biological foundation.

The CEO has cited Korea as second only to the U.S. in terms of global alopecia R&D pipeline depth. With roughly 20 full-time employees, the organization maintains a lean, research-focused venture structure.

Recent trends

For fiscal year 2024 (standalone basis), Epi Biotech posted revenue growth of 56.9% year-on-year, driven by all three business lines: preclinical CRO services, cell line sales, and functional alopecia cosmetics.

At year-end 2024, the company secured its first overseas order from a U.S. biotech, marking a meaningful step toward global business expansion. Operating loss narrowed 35.9% and net loss shrank 55.6% year-on-year, confirming a clear loss-reduction trend.

On the clinical front, EPI-001 received domestic IND approval in December 2023, with the first patient dosing reported to have commenced in H1 2024.

In April 2024, EPI-001 was selected for the government's Pan-Ministry Regenerative Medicine Technology Development Program, providing additional research funding and partially alleviating financial pressure during the clinical phase.

In April 2025, the company signed a China JV and commercialization MOU with Beijing Northland Biotech, and in June 2025 it showcased its full pipeline at a biomed-investor conference in Hainan.

Participation in Bio Japan 2025 (October 2025) included global BD meetings and a public announcement of the company's KOSDAQ listing timeline.

As of June 7, 2026, shares trade at KRW 14,390—modestly below recent highs—while daily trading value remains in the hundreds of thousands of KRW, reflecting the characteristically low liquidity of the KONEX market.

Outlook

Epi Biotech's near-to-medium-term growth path rests on three pillars: successfully completing EPI-001's Phase 1/2a trial and executing a license-out, raising capital through a KOSDAQ technology-based special listing, and entering the Chinese market via the Beijing Northland JV.

The CEO publicly announced the listing timeline at Bio Japan 2025, making the outcome of the technology evaluation and listing approval a key monitoring event for 2026. EPI-001's safety and efficacy data will be pivotal for license-out negotiations and for de-risking the follow-on allogeneic cell therapy EPI-008.

EPI-005, targeting male pattern baldness as a first-in-class antibody, is at the preclinical stage with co-development partners being sought, while the RIPK1 siRNA-based EPI-002 is advancing in collaboration with RNA platform company Qumine.

The Chinese alopecia market holds long-term commercial promise given rapidly rising demand, but the JV and clinical infrastructure are still at an early execution stage, warranting a measured view on timing.

Whether the high-margin CRO business can sustainably fund R&D investment—establishing a genuinely self-sustaining biotech—will be the defining variable for long-term enterprise value.

Bull factors

High-Margin CRO Anchors a Self-Sustaining Biotech Model

The preclinical alopecia CRO business has been reported to carry operating margins above 50%, providing a financial buffer uncommon among pure-play R&D firms.

In 2024, all three revenue lines grew simultaneously, pushing group revenue up 56.9% and yielding the company's first overseas contract with a U.S. biotech—signaling potential for CRO globalization.

The 35.9% and 55.6% reductions in operating and net losses, respectively, confirm that the profitability improvement trajectory is real and ongoing.

If this self-sustaining model continues to solidify, Epi Biotech could reduce its dependency on external capital even post-listing, a differentiating trait in the biotech sector.

Diversified Pipeline with First-in-Class Potential

The range of modalities—autologous cell therapy (EPI-001), allogeneic cell therapy (EPI-008), CXCL12 neutralizing antibody (EPI-005), and RIPK1 inhibitor (EPI-002)—distributes risk across distinct asset classes.

EPI-001 is the most advanced asset with domestic IND approval and ongoing clinical trials, while EPI-005 is considered to have first-in-class potential as the first drug candidate targeting the CXCL12-mediated mechanism in androgenetic alopecia.

The breadth of modalities—spanning cell, antibody, siRNA, and AI platform—allows multiple assets to be put on the table simultaneously in license-out negotiations. The Hair.I AI platform adds incremental attractiveness for external partnerships by enabling data-driven target discovery.

Expanding Global Reach with China as a Key Growth Anchor

In 2025, the company signed a JV and clinical/commercialization MOU with Beijing Northland Biotech, establishing a concrete entry route into the fast-growing Chinese alopecia treatment market.

Participation in global BD forums—Bio Japan and the Hainan biomed conference—has helped generate interest from major pharma and cosmetics companies, broadening the opportunity set for future license-out deals. The 2024 U.S. biotech contract provides tangible evidence that cross-border partnership creation is feasible.

Should the KOSDAQ listing proceed, the capital raised could meaningfully accelerate both global clinical expansion and BD activities.

Bear factors

Extremely Low KONEX Liquidity and Uncertain Transfer Listing

As a KONEX-listed stock, daily trading volume is effectively a few hundred thousand KRW, making meaningful entry or exit impossible for most institutional and retail investors.

While a KOSDAQ technology-based special listing is being pursued, passing the technology evaluation and obtaining listing approval remain unresolved hurdles; delays or rejection could materially disrupt fundraising plans.

Given the micro-cap size, price discovery is structurally limited and fair valuation is difficult to establish. Information asymmetry and restricted investor access are expected to persist until a successful transfer listing is achieved.

Ongoing Operating Losses as a Clinical-Stage Company

Despite the 2024 improvement trend, persistent operating and net losses represent an ongoing cash burn risk. As clinical trial and pipeline development costs rise, the need for external financing remains constant.

Given the still-modest absolute scale of revenues, any loss of a key CRO contract or a slowdown in cosmetics sales could rapidly worsen financial metrics. If the KOSDAQ listing is delayed, bridge financing via convertible bonds could result in meaningful shareholder dilution.

Inherent Clinical Uncertainty Across the Pipeline

EPI-001's Phase 1/2a simultaneously evaluates safety and efficacy; any unexpected adverse events or insufficient efficacy readout would directly damage the company's overall valuation.

As no alopecia cell therapy has yet been commercially approved globally, regulatory pathways and evaluation criteria remain unsettled, keeping regulatory uncertainty elevated.

Follow-on assets EPI-005 (CXCL12 antibody) and EPI-002 (RIPK1 inhibitor) remain at preclinical stages, requiring substantial time and capital before clinical entry. Since license-out is the primary value exit, outcome risk is concentrated on the quality of EPI-001's clinical data.

Risk factors

Macro & Regulatory Risk

Cell therapies are subject to varying approval pathways across national advanced regenerative medicine regulatory frameworks; changes in Korea's Advanced Regenerative Medicine Act or China's cell therapy regulations could directly impact business timelines.

A deterioration in the global interest rate environment or a contraction in biotech investor sentiment could compress the valuation multiple achievable in a KOSDAQ technology-based listing. U.S.-China trade tensions or regulatory tightening could slow the execution and capital flow of the China JV.

As a small-cap entity, the company is also disproportionately exposed to currency fluctuations and raw material cost pressures.

Competitive Risk

The alopecia treatment market includes formidable competitors such as Japan's Shiseido and multiple U.S. biotechs, many of which maintain more advanced clinical pipelines than Epi Biotech.

The autologous cell therapy approach may face inherent disadvantages in accessibility, cost, and manufacturing complexity relative to small-molecule drugs or injectable biologics. The CRO segment could also face accelerating competitive entry as global alopecia research demand grows.

Price competition in the functional alopecia cosmetics category represents an ongoing downward pressure on near-term margins.

Financial & Liquidity Risk

Persistent operating losses combined with a small revenue base structurally accelerate cash burn. If the KOSDAQ technology-based listing is delayed or rejected, external financing alternatives are limited to convertible bonds or rights offerings, both of which carry dilution risk for existing shareholders.

The extremely low KONEX trading liquidity creates a structural pricing distortion and effectively constrains investor exit options.

The potential conclusion of government grants—such as the Pan-Ministry Regenerative Medicine Program—could increase R&D cost burdens and represents an unresolved variable in the company's financial planning.

Overall view

Epi Biotech has established a distinctive biotech model that combines specialized alopecia R&D with a high-margin CRO revenue engine—a meaningful structural differentiator among clinical-stage peers.

The advancement of EPI-001 into clinical trials and the first overseas contract win in 2024 represent tangible operational milestones. The multi-modal pipeline (cell, antibody, siRNA, AI) and China JV strategy provide a credible medium-to-long-term growth narrative.

However, the structural constraints of KONEX-level liquidity, persistent operating losses, early-stage clinical uncertainty, and unresolved KOSDAQ listing risk all argue for a cautious near-term stance.

The EPI-001 Phase 1/2a safety and efficacy readout and progress toward the KOSDAQ transfer listing are the two most critical catalysts for a potential re-rating. At this juncture, a watchful approach—tracking both pipeline advancement and financial sustainability in parallel—appears most appropriate.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 7 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.